Retour
Prix CYBERDYNE Inc. (CYBQF)
Graphique du cours de l'action CYBQF
CYBQF Gagner
CYBERDYNE Inc.
$0
0%
$0
À la fermeture : Feb 13, 16:00:00 GMT-5
$0
0%
$0
Post-Marché: Feb 13, 20:00:00 GMT-5
Earnings FAQ
Comment le bénéfice par action récent de CYBQF se compare-t-il aux attentes ?
Comment les revenus de CYBERDYNE Inc. CYBQF se sont-ils comportés au dernier trimestre ?
Quelle est l'estimation des revenus pour CYBERDYNE Inc. ?
Quel est le score de qualité des bénéfices pour CYBERDYNE Inc. ?
Quand CYBERDYNE Inc. publie-t-elle ses résultats ?
Quels sont les bénéfices attendus de CYBERDYNE Inc. ?
CYBERDYNE Inc. a-t-elle dépassé les attentes en matière de bénéfices ?
Statistiques clés
Clôture préc.
--
Prix d'ouverture
--
Plage de la journée
-
Plage de 52 semaines
-
Volume
--
Volume moyen
--
BPA (TTM)
--
Rendement en dividend
--
Capitalisation boursière
--
Qu’est-ce que CYBERDYNE INC ?
CYBERDYNE, Inc. engages in the research and development of medical welfare equipment and systems. The company is headquartered in Tsukuba-Shi, Ibaraki-Ken and currently employs 211 full-time employees. The company went IPO on 2014-03-26. The firm mainly uses human and the Internet of Things (IoH/IoT), robots, and artificial intelligence (AI) Cybernics technology to develop Cybernic systems. The company develops the Cybernics treatment service business and the training service business that utilize Cybernics technology. The firm develops in various fields centered on HAL. HAL is a robot treatment device for the purpose of improving and regenerating the physical function of patients, a welfare device and life support device for the purpose of supporting independence, and a work support equipment. The company can be used for various purposes by being worn and used by people. The firm is also involved in the productization of AI-equipped transport robots; cleaning robots; Cyin, which is used for communication with people with disabilities, and electrocardiography devices.
Fonctionnalités
Ressources
© 2026 Finture Development Limited. Tous droits réservés.